-
目前许多临床和流行病学资料表明,血浆高密度脂蛋白胆固醇(HDL-C)浓度与急性冠状动脉综合征(ACS)发病危险呈独立负相关关系。HDL-C是一类功能、组成、密度、颗粒大小极不均一的脂蛋白,主要包括两个大的亚群,即高密度脂蛋白2(HDL2)和高密度脂蛋白3(HDL3),HDL-C在参与胆固醇逆转运(RCT)的过程中,其组成、密度及颗粒大小均不断发生改变。这两个亚群与心血管疾病患病危险性的关系可能不尽相同,尽管人们越来越关注HDL-C亚群的生理作用,但到目前为止,关于HDL-C亚类在心血管疾病中的作用的报道数量有限,HDL-C亚类在斑块形成和预防心血管事件中的作用仍有争议[1-2]。本研究探讨HDL3在健康人、稳定性心绞痛(SAP)病人和ACS病人中含量的变化,以明确HDL3与ACS的相关性及其与人群基本特征和HDL3与动脉粥样硬化危险因素的相关性。
-
SAP组和ACS组性别、吸烟、左主干病变(LMS)、病变血管-3支差异有统计学意义(P < 0.05)(见表 1)。SAP组和ACS组总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、HDL-C差异均无统计学意义(P>0.05)(见表 2)。
分组 n 男性 吸烟 高脂血症 糖尿病史 介入史 病变血管-3支 LMS SAP组 58 28(48.28) 12(20.70) 32(55.17) 8(13.79) 0(0.00) 13(22.41) 8(13.79) ACS组 130 85(65.38) 47(36.15) 57(43.85) 23(17.69) 2(1.54) 45(34.62) 37(28.46) χ2 — 3.89 3.37 1.28 1.04 0.58 2.65 3.12 P — < 0.05 < 0.05 >0.05 >0.05 >0.05 < 0.05 < 0.05 表 1 SAP组和ACS组病人的基本特征比较[n;百分率(%)]
分组 n CHOL TG LDL-C HDL-C SAP组 58 4.66±0.94 1.87(0.75~10.34) 2.84±0.69 1.09±0.30 ACS组 130 4.41±0.88 1.63(0.61~4.98) 2.64±0.74 1.07±0.29 t — 1.76 1.31△ 1.75 0.43 P — >0.05 >0.05 >0.05 >0.05 △示uc值 表 2 SAP组和ACS组病人血脂指标水平比较($\overline x \pm s$;mmol/L)
-
3组研究对象血清HDL3水平差异有统计学意义,ACS组HDL3水平低于SAP组(P < 0.05)(见表 3)。
分组 n HDL3/(mg/mL) F P MS组内 正常对照组 47 89.81±41.84 SAP组 58 88.23±41.60 4.25 < 0.05 1 545.470 ACS组 130 73.94±37.29* q检验:与SAP组比较*P < 0.05 表 3 3组HDL3水平比较($\overline x \pm s$)
-
将单因素分析中有统计学意义的因素纳入多因素逐步logistic回归分析模型进行分析,以ACS为因变量,性别、吸烟史、LMS、血管病变-3支、HDL3为自变量,结果显示HDL3水平与ACS的严重程度呈显著负相关关系[B=-0.77, SE=0.25, Waldχ2=3.95, OR(95%CI)0.40(0.20~0.81), P < 0.01]。
高密度脂蛋白3与急性冠状动脉综合征相关性临床分析
Clinical analysis of the correlation between serum level of high density lipoprotein 3 and acute coronary syndrome
-
摘要:
目的分析高密度脂蛋白3(HDL3)与急性冠状动脉综合征(ACS)及其严重程度的相关性。 方法根据冠状动脉造影结果将研究对象分为正常对照组(n=47)、稳定性心绞痛组(SAP,n=58)和急性冠状动脉综合征组(ACS,n=130)。采用酶联免疫吸附法检测血清中HDL3的含量,分析HDL3与ACS及其严重程度的相关性。 结果3组研究对象血清HDL3水平差异有统计学意义,ACS组HDL3水平低于SAP组(P < 0.05)。回归分析显示血清HDL3水平与ACS的严重程度呈显著负相关关系(P < 0.01)。 结论血清HDL3水平与ACS的严重程度呈显著负相关关系,HDL3是ACS的保护因素。 Abstract:ObjectiveTo analyze the correlation between serum level of high density lipoprotein 3 (HDL3) and acute coronary syndrome (ACS). MethodsTwo hundred and thirty-five patients were divided into the control group(n=47), stable angina pectoris group(SAP group, 58 cases) and ACS group(n=130) according to the results of coronary angiography.The serum levels of HDL3 in three groups were measured using ELISA, and the correlation between serum level of HDL3 and ACS was analyzed. ResultsThe differences of the serum levels of HDL3 among three groups were statistically significant, the serum level of HDL3 in ACS group was lower than that in SAP group (P < 0.05).The results of regression analysis showed that the serum level of HDL3 was negatively correlated with the severity of ACS (P < 0.01). ConclusionsThe serum level of HDL3 is negatively correlated with the severity of ACS, and HDL3 is an independent protective factor of ACS. -
表 1 SAP组和ACS组病人的基本特征比较[n;百分率(%)]
分组 n 男性 吸烟 高脂血症 糖尿病史 介入史 病变血管-3支 LMS SAP组 58 28(48.28) 12(20.70) 32(55.17) 8(13.79) 0(0.00) 13(22.41) 8(13.79) ACS组 130 85(65.38) 47(36.15) 57(43.85) 23(17.69) 2(1.54) 45(34.62) 37(28.46) χ2 — 3.89 3.37 1.28 1.04 0.58 2.65 3.12 P — < 0.05 < 0.05 >0.05 >0.05 >0.05 < 0.05 < 0.05 表 2 SAP组和ACS组病人血脂指标水平比较(
;mmol/L)$\overline x \pm s$ 分组 n CHOL TG LDL-C HDL-C SAP组 58 4.66±0.94 1.87(0.75~10.34) 2.84±0.69 1.09±0.30 ACS组 130 4.41±0.88 1.63(0.61~4.98) 2.64±0.74 1.07±0.29 t — 1.76 1.31△ 1.75 0.43 P — >0.05 >0.05 >0.05 >0.05 △示uc值 表 3 3组HDL3水平比较(
)$\overline x \pm s$ 分组 n HDL3/(mg/mL) F P MS组内 正常对照组 47 89.81±41.84 SAP组 58 88.23±41.60 4.25 < 0.05 1 545.470 ACS组 130 73.94±37.29* q检验:与SAP组比较*P < 0.05 -
[1] SALONEN JT, SALONEN R, SEPPANEN K, et al.HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction.A prospective population study in eastern Finnish men[J].Circulation, 1991, 84(1):129. doi: 10.1161/01.CIR.84.1.129 [2] SUPERKO HR, PENDYALAL, WILLIAMS PT, et al.High-density lipoprotein subclasses and their relationship to cardiovascular disease[J].J Clin Lipidol, 2012, 6(6):496. doi: 10.1016/j.jacl.2012.03.001 [3] BARTER P, KASTELEIN J, NUNN A, et al.High Density Lipoproteins (HDLs) and atherosclerosis:the unanswered questions[J].Atherosclerosis, 2003, 168:195. doi: 10.1016/S0021-9150(03)00006-6 [4] STEIN O, STEIN Y.Atheroprotective mechanisms of HDL[J].Atherosclerosis, 1999, 144(2):285. doi: 10.1016/S0021-9150(99)00065-9 [5] TUTEJA S, RADER DJ.High-density lipoproteins in the prevention of cardiovascular disease:changing the paradigm[J].Clin Pharmacol Ther, 2014, 96(1):48. doi: 10.1038/clpt.2014.79 [6] ARSENAULT BJ, LEMIEUX I, DESPRES JP, et al.HDL particle size and the risk of coronary heart disease in apparently healthy men and women:the EPIC-Norfolk prospective population study[J].Atherosclerosis, 2009, 206(1):276. doi: 10.1016/j.atherosclerosis.2009.01.044 [7] AUER J, WEBER T, EBER B.Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J].N Engl J Med, 2004, 351(7):714. doi: 10.1056/NEJM200408123510719 [8] ALBERS JJ, SLEE A, FLEG J, et al.Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial[J].Atherosclerosis, 2016, 251:454. doi: 10.1016/j.atherosclerosis.2016.06.019 [9] JOSHI PH, TOTH PP, LIRETTE ST, et al.Lipoprotein investigators collaborative study, association of high-density lipoprotein subclasses and incident coronary heart disease:The Jackson Heart and Framingham Offspring Cohort Studies[J].Eur J Prev Cardiol, 2016, 23(1):41. doi: 10.1177/2047487314543890 [10] TIOZZO E, GARDENER H, HUDSON BI, et al.High-density lipoprotein subfractions and carotid plaque:the Northern Manhattan Study[J].Atherosclerosis, 2014, 237(1):163.